Works matching DE "REGENERON Pharmaceuticals Inc."
Results: 38
FDA Decision on Dupilumab for COPD Pushed Back to September 2024.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
New frontiers in cardiovascular risk reduction: people with diabetes and dyslipidaemia.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, p. 5, doi. 10.1111/dom.13742
- Publication type:
- Article
Regeneron's Libtayo Surround Program.
- Published in:
- 2018
- Publication type:
- Product Review
Abnormal Uptake and Air Trapping in Hypersensitivity Pneumonitis Detected on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Lay-offs follow suspension of clinical trials of protein.
- Published in:
- Nature, 1994, v. 370, n. 6484, p. 6, doi. 10.1038/370006a0
- By:
- Publication type:
- Article
Search for optimal anti-VEGF dosing strategy in AMD continues.
- Published in:
- Ocular Surgery News, 2009, v. 27, n. 21, p. 19
- Publication type:
- Article
News in brief: Biomedical briefing.
- Published in:
- Nature Medicine, 2012, v. 18, n. 1, p. 10, doi. 10.1038/nm0112-10
- Publication type:
- Article
Business digest.
- Published in:
- Chemistry & Industry, 2013, v. 77, n. 5, p. 19
- Publication type:
- Article
Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye.
- Published in:
- Drugs in R&D, 2008, v. 9, n. 4, p. 261
- Publication type:
- Article
Culture and branding are at the heart of Regeneron Pharmaceuticals' growth strategy.
- Published in:
- Global Business & Organizational Excellence, 2010, v. 29, n. 5, p. 7, doi. 10.1002/joe.20334
- By:
- Publication type:
- Article
Drug developers reboot anti-NGF pain programmes.
- Published in:
- Nature Reviews Drug Discovery, 2015, v. 14, n. 5, p. 297, doi. 10.1038/nrd4612
- By:
- Publication type:
- Article
Trial watch: Atopic dermatitis therapy breakthrough on the horizon?
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 9, p. 645, doi. 10.1038/nrd4414
- By:
- Publication type:
- Article
Market watch: Upcoming market catalysts in Q3 2013.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 7, p. 496, doi. 10.1038/nrd4056
- By:
- Publication type:
- Article
Cholesterol-lowering blockbuster candidates speed into Phase III trials.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 11, p. 817, doi. 10.1038/nrd3879
- By:
- Publication type:
- Article
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 2, p. 98, doi. 10.1038/nrd3667
- By:
- Publication type:
- Article
News in Brief.
- Published in:
- Nature Reviews Drug Discovery, 2008, v. 7, n. 4, p. 280, doi. 10.1038/nrd2566
- Publication type:
- Article
New biologic.
- Published in:
- Formulary, 2008, v. 43, n. 4, p. 120
- Publication type:
- Article
Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii32, doi. 10.1093/bjd/ljad498.035
- By:
- Publication type:
- Article
434 Efficacy and safety of crisaborole ointment, 2%, in Chinese and Japanese pediatric patients aged 2–17 years with mild-to-moderate atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.054
- By:
- Publication type:
- Article
352 Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii38, doi. 10.1093/bjd/ljac140.044
- By:
- Publication type:
- Article
Aflibercept gains new approval, recommendation.
- Published in:
- Optometry Times, 2012, v. 4, n. 10, p. 8
- Publication type:
- Article
Biologics inch toward cholesterol-lowering market.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 4, p. 302, doi. 10.1038/nbt0412-302
- By:
- Publication type:
- Article
Eylea approval transforms Regeneron.
- Published in:
- Nature Biotechnology, 2012, v. 30, n. 1, p. 4, doi. 10.1038/nbt0112-4
- By:
- Publication type:
- Article
Firms chase diabetic inflammation with anti-IL-1β antibodies.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 6, p. 533, doi. 10.1038/nbt0610-533
- By:
- Publication type:
- Article
Biotech in a blink.
- Published in:
- Nature Biotechnology, 2010, v. 28, n. 4, p. 311, doi. 10.1038/nbt0410-311
- By:
- Publication type:
- Article
News in brief.
- Published in:
- Nature Biotechnology, 2007, v. 25, n. 6, p. 613, doi. 10.1038/nbt0607-613
- By:
- Publication type:
- Article
Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2019, v. 9, n. 4, p. 799, doi. 10.1007/s13555-019-00333-2
- By:
- Publication type:
- Article
Aflibercept in clinical practice: Evaluation of the first 50 patients treated with antiVEGF trap for age‐related macular degeneration.
- Published in:
- Acta Ophthalmologica (1755375X), 2012, v. 90, p. 0, doi. 10.1111/j.1755-3768.2012.3662.x
- By:
- Publication type:
- Article
Mouse mAb patent revoked.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 11, p. 1076, doi. 10.1038/nbt1114-1076a
- Publication type:
- Article
The price of priority review: $67.5 million.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 10, p. 973, doi. 10.1038/nbt1014-973
- By:
- Publication type:
- Article
Next-generation AMD drugs to wed blockbusters.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 8, p. 701, doi. 10.1038/nbt0814-701
- By:
- Publication type:
- Article
People.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 5, p. 498, doi. 10.1038/nbt.2911
- Publication type:
- Article
Amgen and Regeneron push for a genetic renaissance in drug discovery.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 3, p. 208, doi. 10.1038/nbt0314-208
- By:
- Publication type:
- Article
Top US universities, institutes for life sciences in 2012.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 10, p. 874, doi. 10.1038/nbt.2719
- By:
- Publication type:
- Article
EU Case Reports.
- Published in:
- Journal of Generic Medicines, 2012, v. 9, n. 3, p. 167, doi. 10.1177/1741134312458519
- By:
- Publication type:
- Article
Developing and Delivering an Effective eCompliance Training Curriculum - An eLearning Case Study.
- Published in:
- Journal of Interactive Instruction Development, 2008, v. 21, n. 2, p. 3
- By:
- Publication type:
- Article
Eyes on New Product Development.
- Published in:
- Journal of Ocular Pharmacology & Therapeutics, 2014, v. 30, n. 9, p. 687, doi. 10.1089/jop.2014.1511
- By:
- Publication type:
- Article
Eyes on New Product Development.
- Published in:
- Journal of Ocular Pharmacology & Therapeutics, 2014, v. 30, n. 5, p. 371, doi. 10.1089/jop.2014.1507
- By:
- Publication type:
- Article